Views & Analysis 5 years of biosimilars in the US: what have we learned? Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.
Views & Analysis Who could replace Sir Andrew Dillon at NICE? With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health
Digital AI-powered drug discovery is outpacing regulators, with Eric... During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.